As both CD26 and CD93 are markers for CML LSC, their gene expression after TKI treatment may change due to the enrichment for HSC-like cells we show in Figure 5c. The gene discussed is DPP4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.